Literature DB >> 8851624

In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.

S P Franzot1, J S Hamdan.   

Abstract

A total of 53 Cryptococcus neoformans strains, including clinical and environmental Brazilian isolates, were tested for their susceptibilities to amphotericin B, 5-flucytosine, ketoconazole, fluconazole, and itraconazole. The tests were performed according to the National Committee of Clinical Laboratory Standards recommendations (document M27-P). In general, there was a remarkable homogeneity of results for all strains, and comparable MICs were found for environmental and clinical isolates. This paper represents the first contribution in which susceptibility data for Brazilian C. neoformans isolates are provided.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8851624      PMCID： PMC163211     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  [In vitro susceptibility of Cryptococcus strains to 5 antifungal drugs].

Authors:  A J Bava; R Negroni
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1989 Sep-Oct       Impact factor: 1.846

3.  Antifungal drug susceptibility testing.

Authors:  J Van Cutsem; H Kurata; H Matsuoka; Y Mikami; M A Pfaller; G M Scalarone; M G Rinaldi
Journal:  J Med Vet Mycol       Date:  1994

4.  Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B.

Authors:  Y Wang; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C).

Authors:  K J Kwon-Chung; I Polacheck; J E Bennett
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

6.  In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome.

Authors:  M Poon; D C Cronin; G P Wormser; E J Bottone
Journal:  Arch Pathol Lab Med       Date:  1988-02       Impact factor: 5.534

7.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; T M Kerkering; P R Goldson; S Shadomy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

8.  Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard.

Authors:  F Barchiesi; A L Colombo; D A McGough; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

9.  Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City.

Authors:  B P Currie; L F Freundlich; A Casadevall
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

10.  Virulence and antifungal susceptibility of environmental and clinical isolates of Cryptococcus neoformans from Puerto Rico.

Authors:  R A Fromtling; G K Abruzzo; A Ruiz
Journal:  Mycopathologia       Date:  1989-06       Impact factor: 2.574
View more
  15 in total

1.  Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure.

Authors:  S P Franzot; J S Hamdan; B P Currie; A Casadevall
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela.

Authors:  B M Calvo; A L Colombo; O Fischman; A Santiago; L Thompson; M Lazera; F Telles; K Fukushima; K Nishimura; R Tanaka; M Myiajy; M L Moretti-Branchini
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

3.  Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

Authors:  M Lozano-Chiu; V L Paetznick; M A Ghannoum; J H Rex
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

4.  DNA fingerprinting pattern and susceptibility to antifungal drugs in Cryptococcus neoformans variety grubii isolates from Barcelona city and rural environmental samples.

Authors:  Yolanda Morera-López; Josep Maria Torres-Rodríguez; Teresa Jiménez-Cabello; Teresa Baró-Tomás; Concepción Alía-Aponte; Marcia S Lázera
Journal:  Mycopathologia       Date:  2005-08       Impact factor: 2.574

5.  Correlation of fluconazole MICs with clinical outcome in cryptococcal infection.

Authors:  A I Aller; E Martin-Mazuelos; F Lozano; J Gomez-Mateos; L Steele-Moore; W J Holloway; M J Gutiérrez; F J Recio; A Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

6.  Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.

Authors:  F E S Mendes; L V N Oliveira; E S Faria; D G Alvarenga; M R Pinto; C P Taborda; B M Soares; P S Cisalpino; D A Santos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-28       Impact factor: 3.267

7.  The isolation, characterization and antifungal susceptibilities of Cryptococcus neoformans from bird excreta in Klang Valley, Malaysia.

Authors:  S T Tay; H C Chai; S L Na; H Hamimah; M Y Rohani; T S Soo-Hoo
Journal:  Mycopathologia       Date:  2005-06       Impact factor: 2.574

8.  Human cryptococcosis: relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas.

Authors:  A C N Delgado; H Taguchi; Y Mikami; M Myiajy; M C B Villares; M L Moretti
Journal:  Mycopathologia       Date:  2005-01       Impact factor: 2.574

9.  In vitro antifungal susceptibility of Cryptococcus gattii.

Authors:  Luciana Trilles; Belkys Fernández-Torres; Márcia dos Santos Lazéra; Bodo Wanke; Josep Guarro
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 10.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.